CHMP Endorses New Add-On Option for Active SLE
Summary
Obinutuzumab could become a new add-on option for autoantibody-positive SLE after a randomized study showed significantly higher response rates vs placebo. Medscape News Europe
Description from Medscape.
Who is covering this
-
CHMP Endorses New Add-On Option for Active SLE
Obinutuzumab could become a new add-on option for autoantibody-positive SLE after a randomized study showed significantly higher response rates vs placebo. Medscape News Europe
Comments
Comments need JavaScript.